Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

(2010) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?

(2010) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

(2010) Leslie Citrome   POSTGRADUATE MEDICINE

A THREE ARM DOSE FINDING STUDY OF LURASIDONE: EFFICACY AND TOLERABILITY DATA

(2010) Philip D. Harvey et al.   SCHIZOPHRENIA RESEARCH

ASSESSMENT OF THE MAXIMUM TOLERATED DOSE (MTD) OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA

(2010) Larry Ereshefsky et al.   SCHIZOPHRENIA RESEARCH

LURASIDONE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA: RESULTS OF THE DOUBLE-BLIND, PLACEBO-CONTROLLED PEARL 2 TRIAL

(2010) Josephine Cucchiaro et al.   SCHIZOPHRENIA RESEARCH

DETECTION OF DRUG-PLACEBO DIFFERENCE IN SCHIZOPHRENIA CLINICAL TRIALS: SITE-RELATED FACTORS

(2010) Antony Loebel et al.   SCHIZOPHRENIA RESEARCH

EFFICACY OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A POOLED ANALYSIS BASED ON A 5-FACTOR MODEL OF SCHIZOPHRENIA

(2010) Antony Loebel et al.   SCHIZOPHRENIA RESEARCH

Using oral ziprasidone effectively: the food effect and dose-response

(2009) Leslie Citrome   ADVANCES IN THERAPY

Lurasidone hydrochloride

(2009) P. Cole et al.   DRUGS OF THE FUTURE

Lurasidone: a new drug in development for schizophrenia

(2009) Jonathan M Meyer et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

(2009) Jan Volavka et al.   EXPERT OPINION ON PHARMACOTHERAPY

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

(2009) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

(2009) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption

(2009) Kuan Gandelman et al.   JOURNAL OF CLINICAL PSYCHIATRY

Lurasidone in the Treatment of Acute Schizophrenia

(2009) Mitsutaka Nakamura et al.   JOURNAL OF CLINICAL PSYCHIATRY

Compelling or irrelevant? Using number needed to treat can help decide

(2008) L. Citrome   ACTA PSYCHIATRICA SCANDINAVICA

A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia

(2008) Stefan Leucht et al.   AMERICAN JOURNAL OF PSYCHIATRY

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks

(2008) Leslie Citrome et al.   Expert Review of Neurotherapeutics

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

(2008) S Leucht et al.   MOLECULAR PSYCHIATRY

Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats

(2007) T ENOMOTO et al.   BEHAVIOURAL BRAIN RESEARCH